India’s Higher Education Opportunity1

Forbes, Naushad

doi:10.1017/cbo9781139096638.009

Cited by 2 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…See https://bit.ly/3iMgyLP, https://bit.ly/3cNd3RE,Kapur et al (2008), Forbes (2013. My own numbers, computed on the basis of intake and enrollment numbers from the All India Council of Technical Education (AICTE) shows that intake (capacity declared by the colleges and approved by AICTE) almost always exceeded enrollment, except in top tier colleges.…”

mentioning

confidence: 99%

Trade, Internal Migration, and Human Capital: Who Gains from India's IT Boom?

Ghose¹

2021

Policy Research Working Papers

View full text Add to dashboard Cite

The Policy Research Working Paper Series disseminates the findings of work in progress to encourage the exchange of ideas about development issues. An objective of the series is to get the findings out quickly, even if the presentations are less than fully polished. The papers carry the names of the authors and should be cited accordingly. The findings, interpretations, and conclusions expressed in this paper are entirely those of the authors. They do not necessarily represent the views of the International Bank for Reconstruction and Development/World Bank and its affiliated organizations, or those of the Executive Directors of the World Bank or the governments they represent.

show abstract

mentioning

confidence: 99%

Trade, Internal Migration, and Human Capital: Who Gains from India's IT Boom?

Ghose¹

2021

Policy Research Working Papers

View full text Add to dashboard Cite

show abstract

“…This resulted in the pandemic-induced growth of new billionaires, and it is reported that the cumulative wealth of the major pharma billionaires in India doubled after 2018. And, it isn't surprising that 15 of India's top 100 billionaires belong to the pharma sector (Forbes, 2021).…”

Section: Is Rising Pharma Market a New Burden?mentioning

confidence: 99%

“…The net worth of Yusuf Hamied, who chairs Cipla, increased over the years of the pandemic, from $1.8 billion in 2019 to $3.91 billion in 2021. In 2021, he was positioned as the country's 51st richest billionaire (Forbes, 2021).…”

Section: Is Rising Pharma Market a New Burden?mentioning

confidence: 99%

“…There was a IJHG 28,2 significant rise in the total revenue and profits of the company at the time of the pandemic due to the same (see Figure 6). Dr. Arvind Lal owns 57% stake in the company and his net worth increased to $2.5 billion in 2021 and was placed as the country's 87th richest person (Forbes, 2021).…”

Section: Is Rising Pharma Market a New Burden?mentioning

confidence: 99%

“…The total net worth of Sudhir and Samir Mehta, the promoters of Torrent Pharma, showed a year-on-year increase of 41.8% in 2021. They ascended to the position of the 25th richest promoters in the country (Forbes, 2021).…”

Section: Is Rising Pharma Market a New Burden?mentioning

confidence: 99%

See 2 more Smart Citations

Is rising pharma market a new burden? Introspecting the implications of India’s healthcare journey from public to a private good

Boddu

Tobi

2023

IJHG

View full text Add to dashboard Cite

PurposeThe paper demonstrates prejudicial effects of the rising private participation and the lacuna of state in ensuring the accessibility and affordability of healthcare.Design/methodology/approachSecondary data analysis from national and international databases is employed to demonstrate the low government spending and the alternate healthcare financing mechanisms in the country. The company reports of six Indian pharma companies are examined to map the profits and revenues, and also taking into account the sales growth and return on investment.FindingsThe paper observes the pharmaceutical sector, via its spiralling drug prices, is the primary contributor to the huge out-of-pocket expenses borne by households. The study findings indicate that there is an increased divergence between the out-of-pocket expenses of households and exorbitant profits of the private drug companies in the country over the years.Research limitations/implicationsAmidst debates on the importance of public health in the aftermath of the pandemic, the paper examines the rising hands of private sector in healthcare, and implores – who benefits? The authors study the implications via looking into the rise in the wealth of pharma giants; at the time of crisis when the lives of common citizens in the country were at stake.Originality/valueThe paper emphasises the repercussions of the higher markup of the pharma industry in raising the healthcare costs of households. The authors emphasise that the nonregulation of the pharma sector leads to high medical debts/poverty, in the wake of growing out-of-pocket expenditures of the citizens.

show abstract

India’s Higher Education Opportunity1

Cited by 2 publications

References 6 publications

Trade, Internal Migration, and Human Capital: Who Gains from India's IT Boom?

Trade, Internal Migration, and Human Capital: Who Gains from India's IT Boom?

Is rising pharma market a new burden? Introspecting the implications of India’s healthcare journey from public to a private good

Contact Info

Product

Resources

About